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Ibuprofen-conjugated and non-ibuprofen cationic carbosilane dendritic molecules show important 






In order to improve the efficiency of the anti-inflammatory drug ibuprofen, cationic carbosilane 
dendrimers and dendrons with ibuprofen at their periphery or at their focal point, respectively, have 
been synthesized and the release of the drug was studied using HPLC. Macrophages were used to 
evaluate the anti-inflammatory effect of the ibuprofen-conjugated dendritic systems and compared 
with mixtures of non-ibuprofen dendritic systems in the presence of the drug. The cationic ibuprofen-
conjugated dendron was the compound that showed higher anti-inflammatory properties. It reduces 
the LPS-induced COX-2 expression, decreases the release of several inflammatory cytokines such as 









Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic and 
antibacterial activity,1-3 and presents good biocompatibility.4 Ibuprofen is a non-selective 
cyclooxigenase (COX) inhibitor that affects two isoforms, COX-1 (which is constitutively expressed 
in many cells and tissues) and COX-2 (which is selectively induced by proinflammatory cytokines at 
the site of inflammation).5 The inhibition of COX-2 blocks the prostaglandins biosynthesis, molecules 
that mediate pathogenic mechanisms as the inflammatory response, and also they are responsible of 
the pain and fever.6 It has been demonstrated that inhibition of COX-2 reverses inflammation and 
expression of interleukin (IL)-6.7 Therefore, treatments of bacterial infections with ibuprofen hasten 
the healing process in vaginal infections, cellulites or acne.8-10 However, its poor solubility joined to 
protein binding, diminishes its bioavailability.11 This problem can be found in many drugs,12 so there 
is a need to develop new platforms for the transport, protection and sustained release of drugs, 
minimizing its side effects, as well as avoiding a fluctuation of the therapeutic concentration.13 Several 
systems have been reported for their use as drug carriers such as vesicles, nanoparticles, polymers.14-19 
Dendrimers are highly branched globular macromolecules which, due to their multivalency, have 
been widely employed in biomedical applications.20 The multivalency of dendrimers, as well as the 
possibility of employing the cavities in their structure, makes them good candidates for obtaining drug 
conjugates that can act as carriers, giving solubility to the drugs and protecting them.21-24 However, 
heterofunctionalization of dendrimers usually implies statistical methods of synthesis, and thus, a loss 
of their characteristic monodispersity. For this reason, other topologies can be used in order to obtain 
drug conjugates while maintaining a defined structure. Similarly to dendrimers, dendrons are highly 
branched cone shaped macromolecules, with a focal point, clearly differentiated from dendritic 
periphery.25 This extra reactive moiety can be used to obtain more complex structures by anchoring 
other structures such as polysaccharides, polymers or nanoparticles.26-29 Few examples of drug-
conjugated dendrons can be found. Bianco et al. reported the synthesis of adamantane based dendrons 




of ibuprofen due to dendrimer multivalency.30 On the other hand, polyester dendrons have been used 
to solubilize the hydrophobic dye BODIPY.31 Finally, previous works of our research group reported 
the synthesis of heterofunctionalized cationic carbosilane dendrons with fluorescein.32, 33 In this case, 
biodistribution studies on carbosilane dendrimers showed their capability to cross the blood brain 
barrier,34 which is an important obstacle in drug delivery to the brain. Regarding ibuprofen modified 
dendrimers, PAMAM-ibuprofen dendrimers improve the drug’s efficacy by enhancing cellular 
delivery, which may produce a rapid pharmacological response35 depending of the linkage between 
dendrimer and drug.36 Also has been reported that ibuprofen solubility increases by electrostatic 
interactions with dendrimers or by conjugation through bond formation.37, 38 
The study of the anti-inflammatory effect induced by compounds with ibuprofen requires an 
appropriate in vitro system, being macrophages the suitable model due to their regulatory capacities in 
inflammatory responses. The immune system is responsible of maintenance the homeostasis on the 
human body. To do it properly, detects pathogens and trigger different immune responses involving a 
wide variety of cells with the aim to eliminate the pathogen. Macrophages are one of the most 
important cells that regulate and trigger different immune responses with the aim to eliminate 
pathogens.39 To trigger an inflammatory response, macrophages must have a pro-inflammatory 
phenotype expressing cytokines such as IL-1β, IL-6 and TNF-α40-42 and exhibiting microbicidal 
functions. These cells are defined as M1-polarized macrophages. Once they have accomplished their 
objective, and therefore an immune response has been successfully activated, macrophages eliminate 
microorganisms by phagocytosis and also restore tissue homeostasis. Macrophages that are acting in 
the resolution of the inflammation are M2-polarized macrophages that present an anti-inflammatory 
phenotype, defined by the production of anti-inflammatory and regulatory cytokines such as IL-10 and 
TGF-β.43, 44 
Herein we deal with the synthesis of cationic carbosilane dendritic macromolecules with one 
ibuprofen unit bonded to them with the aim to evaluate the effect of this drug in these systems. 




a future biological application,45 as this factor will cause significant problems inducing in a non-
controlled way the immune system responses. Moreover, it is well known that some dendritic 
derivatives failed in biological studies performed in vitro due to the inflammatory effect over cells.46 
On the other hand, since cationic carbosilane dendritic molecules have been proved useful as siRNA 
delivery vectors against HIV47-49 and as microbicides,50, 51 and several types of dendrimers have 
shown antiinflammatory activities,49, 52-54 is very interesting to evaluate them as ibuprofen-carriers, 
and also to find whether these structures could help to minimize any inflammatory process, effect that 
could accelerate the healing processes. Finally, the analysis of activity of these compounds would also 
allow verifying their pharmacological action and thus, their potential use as drug delivery systems or 
codrugs.55 
For this purpose, a comparative evaluation of cytokine release by treated macrophages has been 
carried out for cationic carbosilane dendritic molecules with and without an ibuprofen bonded to 
them. Macrophages have been treated with cationic dendritic systems (dendrimer or dendron), with 
combinations of free ibuprofen with cationic carbosilane dendrimers/dendrons, and with ibuprofen-
conjugated cationic systems (dendrimer or dendron). The ibuprofen moiety has been bonded through a 
labile ester bond, using the carboxylic group present in the drug, in order to favor the release of the 
integral drug in optimum conditions.56 
 
MATERIAL AND METHODS 
General considerations 
All reactions were carried out under inert atmosphere and solvents were purified from appropriate 
drying agents when necessary. NMR spectra were recorded on a Varian Unity VXR-300 (300.13 (1H), 
75.47 (13C) MHz) or on a Bruker AV400 (400.13 (1H), 100.60 (13C), 40.56 (15N), 79.49 (29Si) MHz). 
Chemical shifts (δ) are given in ppm. 1H and 13C resonances were measured relative to internal 
deuterated solvent peaks considering TMS = 0 ppm, meanwhile 29Si resonances were measured 




done from HSQC, HMBC, COSY and TOCSY NMR experiments. Elemental analyses were 
performed on a LECO CHNS-932. Mass Spectra were obtained from a Thermo Scientific TSQ 
Quantum LC-MS and an Agilent 6210. Thiol-ene reactions were carried out employing a HPK 125 W 
mercury lamp from Heraeus-Noblelight with maximum energy at 365 nm, in normal glassware under 
an inert atmosphere. Compounds HS(CH2)2NH2·HCl, HS(CH2)2NMe2·HCl, 2,2’-dimethoxy-2-
phenylacetophenone (DMPA), MeI, S-(+)-ibuprofen, K2CO3, Na2CO3, NaOH, porcine liver esterease 








51 were synthesized as previously reported. 
HPLC 
Release of ibuprofen was monitored at 154 nm (10.39 min) using an Agilent Technologies 1200 
series with an Eclipse XDB-C18 5 µM column (Agilent) of 4.6 x 150 mm, with a flux of 1 ml/min and 
a mixture of acetic acid:acetonitrile (50:50) as eluent. In order to quantify the amount of ibuprofen, a 
calibration curve was performed between 15 and 275 mg/l of drug (detection limit is 5 mg/ml, 
quantification limit is 15 mg/ml). Then, PLE (1 unit:1µmol ester) were added to dendritic aqueous 
solutions of a known concentration close to 200 mg/l and incubated. Aliquots were taken at several 
times in order to monitor the release of ibuprofen. The aliquots were measured directly from the 
reaction systems without quenching. In order to check that complete release was possible, an excess of 
PLE was added to the incubated mixtures and drug release was HPLC monitored.  
Synthesis of compounds 
General procedures for the synthesis of compounds are described and a selected number of 
compounds are collected below. The complete list of compounds is collected in the supplementary 
information. 
Procedure 1: thiol-ene addition 
To a dendrimer or dendron solution (THF:MeOH, 1:2) decorated with vinyl groups, 1.05 




was used as initiator in a 5 % mol regarding the double bonds. The mixture was deoxygenated and 
irradiated for 1.5 h (λmáx = 364 nm). After this time, another 5 % mol of DMPA was added and the 
mixture was again deoxygenated and irradiated for 1.5 h. Afterwards volatiles were removed under 
vacuum and compounds were purified using nanofiltration (Stirred Ultrafiltration Cells from 
Millipore) or dialysis in water, using membranes with the adequate molecular weight cut off 
according to the size of the corresponding dendritic systems (see experimental in supplementary 
information). 
In the case in which two different thiols were employed, the first derivative was added in a 
stoichiometric amount, according to the number of vinyl groups to be modified, and irradiated for 30 
minutes in the same conditions than those described above. Then, the rest of the periphery was 
functionalized using the procedure above described after addition of the corresponding amount of the 
second thiol. 
Procedure 2: neutralization of –NMe2·HCl 
To a dendritic solution in a mixture of H2O/CHCl3 (1:1), an aqueous solution of NaOH or Na2CO3 
(1.3 equivalents regarding the –NMe2·HCl groups) was added. The reaction mixture was stirred for 15 
minutes at room temperature and then, the organic phase was separated and dried with Na2SO4. 
Finally, volatiles were removed under vacuum to obtain the desired products. 
Procedure 3: quaternization of amines with MeI 
In a schlenk, the desired amount of G2O3(OH)(NMe2)11 or IbuCO2Gn(NMe2)m was solved in a 
mixture of dry Et2O and THF (10:1). Afterwards, excess MeI (1.05 equivalents per amine) was added 
at room temperature. The mixture was stirred at room temperature overnight under inert atmosphere 
and afterwards volatiles were removed under vacuum and products were washed with hexane. 
Procedure 4: Introduction of ibuprofen at the focal point of dendrons 
To a DMF solution of BrGnVm the stoichiometric amount of S-(+)-ibuprofen was added in 
presence of two equivalents of K2CO3, 0.1 equivalents of 18-crown-6 and catalytic amounts of NaI. 




Et2O/NH4Cl (ac) extraction was performed. The organic phase was dried under MgSO4 and solvent 
removed under vacuum to obtain the desired compounds as oils. 
G2O3(OH)(NMe2·HCl)11 (2). Procedure 1. Step 1: G2O3V12 (0.575 g, 0.46 mmol), 2-
mercaptoethanol (0.03 ml, 0.46 mmol) and DMPA (0.012 g, 0.04 mmol); Step 2: 2-
(dimethylamino)ethanethiol hydrochloride (0.788 g, 5.28 mmol) and DMPA (0.129 g, 0.50 mmol). 
Compound 2 was obtained as a white powder (0.127 g, 82 %). 
1H NMR (DMSO-d6): δ -0.07 (s, 9 H, OC4H8SiMe), 0.01 (s, 18 H, SiMeC2H4S), 0.58 (m, 30 H, 
OCH2CH2CH2CH2SiCH2 and CH2SiC2H3), 0.85 (m, 24 H, SiCH2CH2S), 1.32 (m, 18 H, 
OCH2CH2CH2CH2Si and SiCH2CH2CH2Si), 1.67 (m, 6 H, OCH2CH2CH2), 2.57 (m, 24 H, 
SiCH2CH2S), 2.73 (s, 68 H, SCH2CH2O and .-NMe2H
+), 2.87 (m, 22 H, SCH2CH2N
+ and 
SCH2CH2O), 3.19 (m, 20 H, CH2N
+), 3.50 (m, 2 H, SCH2CH2O), 3.88 (m, 6 H, OCH2CH2CH2), 6.01 
(s, 3 H, C6H4). 
13C{1H} NMR (DMSO-d6): δ -5.7 and -5.4 (SiMe), 12.7 (OCH2CH2CH2CH2Si), 13.5 
(SiCH2CH2SC2H4N
+), 13.8 (SiCH2CH2SC2H4O), 16.9-17.6 (SiCH2CH2CH2Si), 19.5 (OCH2CH2CH2), 
24.3 (SiCH2CH2SC2H4N
+), 26.0 (SCH2CH2N
+), 26.4 (SiCH2CH2SC2H4O), 32.1 (OCH2CH2CH2), 33.2 
(SCH2CH2O), 41.4 (-NMe2H
+), 55.3 (CH2N
+), 60.4 (SCH2CH2O), 66.6 (OCH2CH2CH2), 93.1 (C6H4, 
C-H), 160.0 (C6H4, C-O). Anal. Calc. C115H264Cl11N11O4S12Si9 (2892.93 g/mol): C, 47.75; H, 9.20; N, 
5.33; S, 13.30; Obt.: C, 48.21; H, 8.71; N, 5.69; S, 12.01. 
G2O3(OH)(NMe2)11 (3). Procedure 2. Data: 2 (0.600 g, 0.21 mmol) and NaOH (0.100 g, 2.50 
mmol). Compound 3 was obtained as yellowish oil (0.418 g, 81 %). 
1H NMR (CDCl3): δ -0.08 (s, 9 H, OC4H8SiMe), 0.00 (s, 18 H, SiMeC2H4S), 0.54 (m, 30 H, 
OCH2CH2CH2CH2SiCH2 and CH2SiC2H3), 0.87 (t, Ja = 8.7 Hz, 24 H, SiCH2CH2S), 1.28 (m, 12 H, 
SiCH2CH2CH2Si), 1.41 (m, 6 H, OCH2CH2CH2CH2Si), 1.75 (m, 6 H, OCH2CH2CH2), 2.24 (s, 66 H, -
NMe2), 2.48 (m, 22 H, SCH2CH2N), 2.51 (m, 24 H, SiCH2CH2S), 2.57 (m, 22 H, SCH2CH2N), 2.70 
(m, 2 H, SCH2CH2O), 3.68 (m, 2 H, SCH2CH2O), 3.88 (m, 6 H, OCH2CH2CH2), 6.04 (s, 3 H, C6H4). 
13C{1H} NMR (CDCl3): δ -5.2 and -5.1 (SiCH3), 13.8 (OCH2CH2CH2CH2Si), 14.7 (SiCH2CH2S), 




33.3 (OCH2CH2CH2), 35.0 (SCH2CH2O), 45.3 (-NMe2), 59.2 (CH2N
+), 60.7 (SCH2CH2O), 67.7 
(OCH2CH2CH2), 93.7 (C6H4, C-H), 160.9 (C6H4, C-O). Anal. Calc. C115H253N11O4S12Si9 (2491.86 
g/mol): C, 55.43; H, 10.23; N, 6.18; S, 11.99. Obt.: C, 55.81; H, 10.23; N, 6.69; S, 11.89. 
G2O3(OCOIbu)(NMe2)11 (4). A dry DMF solution of 3 (0.114 g, 0.04 mmol), 2 equivalents of S-
(+)-ibuprofeno (0.019 g, 0.09 mmol) and 4 equivalents of DMAP (0.047 g, 0.18 mmol) was stirred 
overnight at room temperature under inert atmosphere in a valved ampoule. Then, 4 equivalents of 
EDCI (0.035 g, 0.18 mmol) were added and the solution was heated at 60 ºC for 2 days. Afterwards, 
volatiles were removed, THF was added and after filtering, a size exclusion chromatographic column 
(Bio-Beads SX-1, Bio-Rad) was performed in THF obtaining 4as yellowish oil (0.115 g, 93 %). 
1H NMR (CDCl3): δ -0.07 (s, 9 H, OC4H8SiMe), -0.01 (s, 18 H, SiMeC2H4S), 0.55 (m, 30 H, 
OCH2CH2CH2CH2SiCH2CH2CH2Si), 0.86 (m, 30 H, SiCH2CH2S and CH(CH3)2), 1.26 (m, 21 H, 
SiCH2CH2CH2Si), 1.42 (m, 6 H, OCH2CH2CH2CH2Si), 1.45 (d, J = 7.2 Hz, 3 H, CH(CH3)CO), 1.76 
(m, 7 H, OCH2CH2CH2 y CH(CH3)2), 2.21 (s, 66 H, -NMe2), 2.42 (m, 2 H, CH2Ar), 2.47 (m, 22 H, 
SCH2CH2N), 2.50 (m, 24 H, SiCH2CH2S), 2.57 (m, 22 H, SCH2CH2N), 2.70 (m, 2 H, SCH2CH2O), 
3.88 (m, 6 H, OCH2CH2CH2), 4.17 (m, 2 H, CH2OCO), 6.05 (s, 3 H, C6H4), 7.10 and 7.16 (m, 4 H, 
Ar, C-H). 13C{1H} NMR (CDCl3): δ -5.3 and -5.1 (SiCH3), 13.5 (OCH2CH2CH2CH2Si), 14.6 
(SiCH2CH2S), 18.3-18.6 (SiCH2CH2CH2Si and (CH3)CH), 20.5 (OCH2CH2CH2), 22.4 (CH(CH3)2), 
27.6 (SiCH2CH2S), 29.5 (SCH2CH2N), 30.1 (CH(CH3)2), 33.2 (OCH2CH2CH2), 34.9 (SCH2CH2O), 
45.0 (CHCO), 45.2 (-NMe2), 45.4 (CH2Ar), 59.1 (CH2N
+), 63.6 (SCH2CH2O), 67.9 (OCH2CH2CH2), 
93.6 (C6H4, C-H), 127.1 and 129.3 (C6H4(Ibu), C-H), 137.5 y 140.5 (C6H4(Ibu), C-H), 160.9 (C6H4, C-
O), 174.5 (C=O). Anal. Calc. C128H269N11O5S12Si9 (2680.13 g/mol): C, 57.36; H, 10.12; N, 5.75; S, 
14.36; Obt.: C, 57.61; H, 9.84; N, 5.29; S, 14.06. 
G2O3(OCOIbu)(NMe3I)11 (5). Procedure 3. Data: 4 (0.028 g, 0.01 mmol) and MeI (0.01 ml, 0.13 
mmol). Compound 5 was obtained as a yellowish powder (0.028 g, 65 %). 
1H NMR (DMSO-d6): δ -0.06 (s, 9 H, OC4H8SiMe), 0.04 (s, 18 H, SiMeC2H4S), 0.56 (m, 30 H, 




H, SiCH2CH2CH2Si and CHCH3), 1.43 (m, 6 H, OCH2CH2CH2CH2Si), 1.75 (m, 7 H, OCH2CH2CH2 
and CH(CH3)2), 2.63 (m, 24 H, SiCH2CH2S), 2.90 (m, 22 H, SCH2CH2N
+), 3.10 (s, 99 H, -NMe3
+), 
3.53 (m, 22 H, SCH2CH2N
+), 3.86 (m, 6 H, OCH2CH2CH2), 4.13 (m, 2 H, CH2OCO), 6.01 (s, 3 H, 
C6H4), 7.08 and 7.15 (m, 4 H, Ar, C-H). 
13C{1H} NMR (DMSO-d6): δ -5.7 (SiCH3), 13.7 
(SiCH2CH2S), 17.4 (SiCH2CH2CH2Si), 19.6 (OCH2CH2CH2), 21.7 (CH(CH3)2), 23.1 (SiCH2CH2S), 
26.4 (SCH2CH2N), 29.1 (OCH2CH2CH2), 43.7 (CH2Ar), 47.8 (-NMe3
+), 64.0 (CH2N
+), 126.6 and 
128.7 (C6H4(Ibu), C-H). Anal. Calc. C139H302I11N11O5S12Si9 (4241.45 g/mol): C, 39.36; H, 7.18; N, 
3.63; S, 9.07; Obt.: C, 38.80; H, 7.17; N, 3.16; S, 9.36. 
IbuCO2G3V8 (8). Procedure 4. Data: BrG3V8 (0.627 g, 0.69 mmol), IbuCO2H (0.142 g, 0.69 
mmol), K2CO3 (0.191 g, 1.38 mmol) and 18C6 (0.017 g, 0.06 mmol). Yellow oil (0.669 g, 94 %). 
1H NMR (CDCl3):δ -0.12 and -0.11 (s, 9 H, SiMe), 0.11(s, 12 H, SiMeC2H3), 0.42 (t, Ja = 8.4 Hz, 2 
H, OCH2CH2CH2CH2Si), 0.53 (m, 16 H, SiCH2CH2CH2Si, overlapped), 0.68 (t, Jb = 8.1 H, 
CH2SiC2H3), 0.87 (d, Jc = 6.6 Hz, 6 H, (CH3)2CH), 1.32 (m, 14 H, OCH2CH2CH2CH2Si and 
SiCH2CH2CH2Si), 1.46 (d, Jd= 7.2 Hz, 3 H, CH(CH)3CO), 1.57 (m, 2 H, OCH2CH2), 1.80 (m, 1 H, 
(CH3)2CH), 2.42 (d, Je = 6.9 Hz, 2 H, CH2Ar), 3.64 (q, Je = 6.9 Hz, 1 H, CHCO), 4.03 (t, Jf = 6.4 Hz, 2 
H, OCH2), 5.68 and 6.06 (m, 24 H, SiCHCH2), 7.07 and 7.16 (m, 4 H, Ar, C-H). 
13C{1H} NMR 
(CDCl3): δ -5.2 and -5.0 (SiCH3), 13.6 (OCH2CH2CH2CH2Si), 18.3–18.9 (SiCH2CH2CH2Si and 
(CH3)CH), 20.2 (OCH2CH2CH2CH2Si), 22.4 ((CH3)2CH), 30.2 ((CH3)2CH), 32.4 
(OCH2CH2CH2CH2Si), 45.0 (CHCO), 45.2 (CH2Ar), 64.5 (OCH2), 127.1 and 129.2 (Ar, C-H), 132.6 
(SiCHCH2), 137.2 (SiCHCH2), 137.8 y 140.4 (Ar, Cipso), 174.8 (C=O). 
29Si NMR (CDCl3): δ 1.6 (G1–
Si), 1.0 (G2–Si), -13.3 (G3-SiCHCH2). Anal. Calcd. C58H106O2Si7 (1032.06 g/mol): C, 67.50; H, 10.35; 
Exp.: C, 67.12; H, 10.00.  
Macrophage differentiation and cell culture 
Blood samples were obtained from buffy coats of healthy donors from the Transfusion Center of 
Madrid respecting national guidelines. Peripheral blood mononuclear cells (PBMCs) were isolated by 




cultured at 0.5 x 106 cells/mL for 7 days in RPMI medium supplemented with 10% foetal bovine 
serum (FBS) and 1000 U/mL of recombinant human granulocyte macrophage-colony stimulating 
factor (rh GM-CSF) (ImmunoTools) or 10ng/mL of recombinant human macrophage-colony 
stimulating factor (rhM-CSF) (ImmunoTools) to generate M1 and M2 monocyte–derived 
macrophages respectively. Cytokines were added every 2 days. It was verified that the differentiated 
macrophages had the proper phenotype (size and morphology) for subsequent experiments (figure 
S1). 
MTT assay 
Monocytes were differentiated into M1 or M2 during 7 days as mentioned above. Macrophages 
were treated with dendrimers or dendrons and mitochondrial metabolism was evaluated by detecting 
the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium-bromide (MTT) as indicator of 
toxicity. Macrophages (M1 and M2) were plated (7.5x104 macrophages per condition, distributed in 3 
wells in a 96 well plate), and treated with cationic carbosilane dendrimers or dendrons at different 
concentrations (5-20M) for 24 hours. MTT was added at 0.5mg/mL (in Dulbecco's Modified Eagle's 
Medium) and incubated during four hours at 37ºC. The plate was centrifuged, the supernatant 
removed and the reaction was stopped by adding DMSO (50μL per well). The plate was shaked for 5 
minutes and analyzed in a plate reader at 570nm and the reference used was absorbance at 690nm. 
Viability was calculated by normalizing data to untreated cells, and referred to 100%. Conditions 
which their 2xSEM (confidence interval of 95%) do not include values equal or greater than 80% 
were rolled out. 
CASY® Cell Counter 
Viability was evaluated using the CASY® Cell Counter. Monocytes were differentiated into M1 
or M2 during 7 days as mentioned above. The 7th day 3x105 macrophages per condition (M1 or M2) 
were counted and turn them to the plate to adhere over night. Cationic carbosilane dendrimers or 
dendrons were added in the culture plate at 3M or 5M. After 24 hours cells were washed with PBS, 




corrected by the dilution factor and cells per mL were calculated. Viability was calculated by 
normalizing data to untreated cells, and referred to 100%. Conditions that their 2xSEM (confidence 
interval of 95) does not include values equal or greater than 80% were discard. 
Quantitative real-time PCR 
Three combinations of different conditions were tested. The first condition was: M1 and M2 were 




+)8 (19), or IbuCO2G3(NMe3
+)8 (17) at 5 μM for 24 hours. The second condition 
was: M1 and M2 were treated with ibuprofen or compounds at 5 μM for 30 minutes and then treated 
with LPS (10ng/ml) for 24 hours. The third condition was: M1 and M2 were treated with LPS at 
10ng/ml for 30 minutes and then were treated with ibuprofen or compounds for 24 hours. 
Subsequently, RNA of all samples was extracted by using the RNeasy Plus mini kit (Qiagen). RNA 
integrity was analyzed with Agilent 2100 bioanalyzer (Agilent Technologies) by using RNA Nano 
chips (Agilent Technologies). A reverse transcriptase was used to generate complementary DNA 
(cDNA) from RNA templates (reverse transcription) with the GoScript Reverse Transcription System 
(Promega). mRNA expression was analyzed by qRT-PCR using specific probe and primers for COX-2 
(designed by using the Universal Human Probe Roche library system, Roche Diagnostics). Results 
were processed with the iQ5 2.0 software (Bio-Rad). Data was normalized according to the expression 
levels of a housekeeping gene (TATA-binding protein, TBP), and expressed relative to the mRNA of 
untreated samples (relative mRNA). 
Cytokines release 
Macrophages (M1 and M2) were treated with LPS (Sigma-Aldrich) at 10ng/ml for 24 hours, or 
pre-treated with ibuprofen or compounds at 5 μM for 30 minutes and after treated with LPS for 24 
hours; or pre-treated with LPS for 30 minutes and after treated with ibuprofen or compounds for 24 
hours. Then, supernatants were collected and amount of cytokines and chemokines were determined 
(TNFα, IL-8, IL-6, CCL3 and IL-1β in M1 cultures; and TNFα, IL-8, CCL3, IL-10, CXCL9and 




by manufacturer. Gallios Beckmann Coulter cytometer was used and data was analyzed by 
FlowCytomixPro software, version 3.0. 
 
RESULTS AND DISCUSSION 
As commented above, we report the synthesis of ibuprofen conjugated cationic carbosilane 
dentritic molecules through a labile ester bond. The ammonium groups decorating dendritic molecules 
are of the type - NMe3
+, since carbosilane dendrimers and dendrons with more acidic -NR2H
+ 
functions become insoluble if the proton is released from their structure, due to the highly 
hydrophobic framework of these macromolecules. To simplify the nomenclature of dendritic 
structures they will be named as GnO3Ym for dendrimers and XGnYm for dendrons, where Gn stands 
for the dendritic generation and Ym for the peripheral functions and its number; O3 denotes the 
polyphenoxo moiety used as a core in dendrimers, and X refers to the group placed in the focal point 
of dendrons. 
For the synthesis of a cationic dendrimer with ibuprofen bonded through an ester bond (scheme 1) 
we required the presence of a hydroxyl function on the periphery for further attached of ibuprofen via 
Steglich esterification, and amine groups, precursors of cationic ammonium groups. With this in mind, 
starting from the vinyl dendrimers G2O3V12, two consecutive thiol-ene addition reactions were carried 
out, following the synthetic procedure previously described for homofunctionalized dendrimers.57 
First, the treatment with one eq. of 2-mercaptoethanol and subsequently with excess 2-
(dimethylamino)ethanethiol hydrochloride, led to dendrimer G2O3(OH)(NMe2H
+)11 (2), which after 
base treatment afforded neutral derivative G2O3(OH)(NMe2)11 (3).Once obtained dendrimer 3, 
addition of ibuprofen was performed in dry DMF using DMAP (4-dymethylaminopyridine) as a base 
and EDCI (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) as a coupling agent, leading to 
ibuprofen-conjugated dendrimer G2O3(OCOIbu)(NMe2)11 (4), which after reaction with MeI allowed 
us to obtain the target productG2O3(OCOIbu)(NMe3
+)11 (5) as a water soluble solid in high yields 





Scheme 1. Synthesis of the ibuprofen conjugated cationic dendrimer G2O3(OCOIbu)(NMe3
+)11 
(5).i) HS(CH2)2OH, hν, DMPA; ii) HS(CH2)2NMe2HCl, hν, DMPA; iii) NaOH; iv) S-(+)-ibuprofen, 
DMAP, EDCI; v) MeI. 
Functionalization with first thiol compound to prepare G2O3(OH)V11 (1) was followed by NMR, 
which showed the appearance of two signals at around δ 0.9 and 2.5, in 1H-NMR, and 15 and 27, in 
13C-NMR, corresponding to the new formed chain SCH2CH2Si.The signals due to 2-mercaptoethanol 
could be observed at c.a. δ 2.7, 2.8 and 3.7, in the1H-NMR spectrum, and at c.a. δ 35 and 60, in 
the13C-NMR spectrum. Also, the1H-NMR spectrum corroborated the presence of this moiety in the 
established proportion by comparison of the new signals and the ones corresponding to the non-
reacted vinyl groups. The spectroscopic data of compounds 2 and 3, showed the expected signals due 
to the introduction of the second thiol derivative.57 For the heterofunctionalized ibuprofen-dendrimers 
G2O3(OCOIbu)(NMe2)11 (4) and G2O3(OCOIbu)(NMe3
+)11 (5), confirmation of ester bond formation 
was done by the resonances corresponding to the methylene group directly attached to ibuprofen at 
c.a. δ 4.1 (from δ 3.7 in compound 3) and 64 in 1H- and 13C-NMR spectra, respectively. Also, the 
resonances due to the presence of the ibuprofen fragment were observed (figure S3). Finally, a DOSY 
NMR experiment showed a unique diffusion coefficient for compounds 4 and 5. The same experiment 
for a mixture of the corresponding homofunctionalized dendrimer and ibuprofen showed one diffusion 





Figure 1. Drawing of selected cationic ibuprofen-conjugated and non-ibuprofen dendritic 
molecules. Iodide anions are omitted for clarity. 
 
Regarding dendrons, introduction of the ibuprofen moiety at the focal point was afforded by 
nucleophilic substitution of the bromide atom in BrGnVm (n = 1, m =2; n =2, m = 4; n = 3, m = 8)
58 by 
the carboxylic moiety in ibuprofen (scheme S1), avoiding the use of coupling agents. The new 
dendrons IbuCO2GnVm (n = 1, m =2 (6); n =2, m = 4 (7); n = 3, m = 8 (8)) thus formed were easily 
purified by simple water/Et2O extraction. The presence of this ibuprofen moiety in dendrons 6-8 was 
confirmed by NMR spectroscopy. The original resonances of the methylene BrCH2 disappear (δ 3.40 
in the 1H-NMR spectra) and new resonances belonging to the methylene CO2CH2 at the focal point 
bound to ibuprofen were observed at c.a. δ 4.0 and c.a. δ 64 in 1H- and 13C-NMR spectra, 




observed. Next, following an identical protocol than for dendrimers (see above), the cationic dendrons 
IbuCO2Gn(NMe3
+)m (15-17, scheme S1, figure 1, figure S2) were obtained. 
These compounds were characterized by NMR spectroscopy, mass spectrometry (MS) and 
elemental analyses. Their NMR characteristics were also analogous to those of dendrimer but for the 
presence of the focal chain, which resonances were as those described in dendrons 6-8. That is, the 
presence of the ibuprofen bound through an ester bond is confirmed by the resonances belonging to 
the methylene group CO2CH2 directly attached to this group at c.a. δ 4.1 and c.a. δ 64 in the 
1H- and 
13C-NMR spectra, respectively. Moreover, in the MS were detected peaks corresponding to the whole 
cationic dendritic structure containing ibuprofen. On the other hand, HPLC did not show the presence 
of free ibuprofen in cationic dendrons 15-17. 
 
Figure 2. Release of ibuprofen (%, HPLC) after addition of 1 unit of porcine liver esterease (PLE) 
per ester bond at different times (hours, h) for dendrimer G2O3(OCOIbu)(NMe3
+)11 (5) and dendrons 
IbuCO2Gn(NMe3
+)m (n = 1, m =2 (15); n =2, m = 4 (16); n = 3, m = 8 (17)). 
 
The purpose of introducing an ibuprofen moiety in cationic derivatives 5 and 15-17 is obtaining a 
combined action between the cationic dendritic framework and the anti-inflammatory drug. Hence, the 
release of ibuprofen in an adequate environment should be produced. Although the synthesized 
compounds are stable in aqueous media, even at slightly acid pH, it must be considered that in the 
organism there are hydrolytic enzymes able to break the ester bonds. For this reason, dendrimer 
G2O3(OCOIbu)(NMe3
+)11 (5) and dendrons IbuCO2Gn(NMe3




presence of porcine liver esterase (PLE, 1 µmol ester: 1 unit) and the release of ibuprofen was 
monitored at several times using HPLC. After addition of esterase, a certain amount of ibuprofen, 
dependent on the compound, was released (figure 2). Although it turned out impossible to establish a 
relationship between the structure and the amount of drug released, it must be highlighted that it might 
be related with the conformation of these compounds in aqueous solutions. These dendritic systems 
contain hydrophobic, ibuprofen ligand and carbosilane framework, and hydrophilic, ammonium 
groups, moieties and therefore, the exposure of the hydrophobic parts in aqueous solution tend to be 
minimized. For this reason, the accessibility of the ester bond can randomly vary for these 
compounds. Addition of extra portions of esterase reactivated the released process. 




+)8 (19), or IbuCO2G3(NMe3
+)8 (17), bound or not 
with ibuprofen, on the inflammatory response mediated by macrophages. The selection of the second 
generation dendrimers and a third generation dendrons for these assays was done on the basis of 
previous studies on cationic carbosilane dendrimers for gene therapy, which showed that the best 
relationship between activity and toxicity were for these systems than for lower or higher generation 
derivatives.32, 47 
The mRNA of the inducible cyclooxigenase (COX-2) expression was quantified on M1 and M2 
macrophages treated with different molecules at 5 μM as non-toxic doses (establish by an MTT assay 
and confirmed with the electronic cell sizer CASY® Cell Counter, supplementary figure S5). 
Separately, macrophages were treated with bacterial lipopolysaccharide (LPS), a complex glycolipid 
present on the outer membrane of Gram-negative bacteria, which is one of the most potent microbial 
initiators of inflammation.60 For those properties, LPS was used as an inflammatory activator stimulus 
responsible for the production of prostaglandins and inflammatory processes. Results show that none 






Figure 3. Quantification of gene expression on treated macrophages by Q-PCR.COX-2 mRNA 
expression was determined by Q-PCR in M1 (A) and M2 (B) untreated or treated with either 




+)8 (19), or IbuCO2G3(NMe3
+)8 (17) for 24 hours. Data shows relative mRNA 
levels; analyzed gene was normalized to TATA box binding protein expression (TBP) and referred to 
non-treated cells (NT). Mean and SD of triplicates are shown. One-sample t test, confidence intervals 
95% of the mean (versus NT). *p ≤ 0.05. 
 
A lipopolysaccharide (LPS) was used as an activator stimulus over M1 and M2cells (figure 4). 
Macrophages were treated with dendritic derivatives previously (pre-treatment; figure 4A and 4B) or 
subsequently (post-treatment; figure 4C and 4D) at LPS stimulation. Also, to evaluate the effect of 
ibuprofen released bydendrimer5 and dendron 17, macrophages were treated with with free ibuprofen 
and corresponding dendrimer18 and dendron 19, simulating the in vitro release of the drug. Results 
show that cells treated with ibuprofen, before or after the LPS stimulus, decrease the LPS-induced 




expected. For pre-treated M1 cultures, all tested treatments reduced the LPS-induced expression of 
COX-2 in a similar way than ibuprofen did (figure 4A). However, post-treated M1 cells with cationic 
systems show improved reductions on COX-2 expression compared with ibuprofen (figure 
4C).Regarding M2-treated cells, and despite slight differences between pre-treatment and post-
treatment, both cationic dendrons 17 and 19 and cationic dendrimer without ibuprofen 18 reduce the 
LPS-induced COX-2 expression (figure 4B and 4D). On the contrary, ibuprofen-conjugated dendrimer 
5 do not decrease the induction on COX-2 expression induced by LPS over M2 (figure 4B and 4D) 




+)8 (19) and 
IbuCO2G3(NMe3
+)8 (17) as non-inflammatory molecules, and at least three of them, 17, 19 and 18, 
reduces the LPS-induced COX-2 expression in both polarization states of macrophages. These are 
encouraging results since COX-2 inhibition decreases the synthesis of prostaglandins, molecules 





Figure 4. Quantification of gene expression on treated macrophages by Q-PCR.COX-2 mRNA 
expression was determined by Q-PCR in M1 (A, C) and M2 (B, D). Results on non-treated cells (NT), 
stimulated with lipopolysaccharide (LPS) or treated with G2O3(OCOIbu)(NMe3
+)11 (5) or 
IbuCO2G3(NMe3
+)8 (17) previously (A, B) or subsequently (C, D) at stimulating with LPS are shown. 
Separately, macrophages were treated with free ibuprofen and G2O3(NMe3
+)12 (18) 
orHOC2H4OG3(NMe3
+)8 (19) previously (A, B) or subsequently (C, D) at stimulating with LPS. Data 
shows relative mRNA levels; analyzed gene was normalized to TATA box binding protein expression 
(TBP) and referred to non-treated cells (NT). Mean and SD of triplicates are shown. One-sample t 
test, confidence intervals 95% of the mean (versus LPS). *p ≤ 0.05, **p < 0.01, ***p < 0.001. 
 
Concerning inflammatory response, when macrophages are confronted with pathogens, as in case 
of a bacterial infection, they secrete cytokines and chemokines; these are soluble peptides that play an 
important role on the development and maintenance of inflammatory process. These molecules have 
an effect over many signal transduction pathways that regulate cellular differentiation, and further, 
they are responsible of the recruitment of neutrophiles, macrophages, among other cells to specific 
inflammatory sites. Regarding the study of molecules involved in inflammatory processes, it is 
important to evaluate the molecule-induction of the inflammatory response triggered by M1but also to 
evaluate whether compounds allow the normal resolution of this status. Once the inflammatory 
response eliminates the pathogen, the anti-inflammatory macrophages (M2) play an important role 
down-regulating the inflammatory mediators to re-establish a homeostatic environment; this is the 
resolution phase of an inflammatory response. Therefore, depending on the cellular polarization state, 
macrophages present different cytokines and chemokinesprofiles.62, 63It is well known that several 
cytokines are involved in particle-induced inflammation,64 hence, the evaluation of cationic dendritic 
systems with and without bound ibuprofen over cytokines release by LPS-stimulated M1 




evaluated to determine whether these treatments could improve the effect of ibuprofen, either 
downloading proinflammatory or raising anti-inflammatory cytokines. 
 
Figure 5. Cytokines release by M1 macrophages. Quantification of TNFα (A), IL-1β (B), IL-8 
(C), IL-6 (D) and CCL3 (E) release in M1 cultures supernatants. Shown non-treated cells (NT), 




+)12 (18+LPS) or G2O3(OCOIbu)(NMe3
+)11 
(5+LPS) for 30 min previously at stimulating with LPS for 24 h. Also shown macrophages treated 
with HOC2H4OG3(NMe3
+)8 ((19+Ibu)+LPS) or G2O3(NMe3
+)12 ((18+Ibu)+LPS) and free ibuprofen 
for 30 min previously at stimulating with LPS for 24 h. Individual values from one donor are shown. 
 
For these assays, macrophages were treated with ibuprofen-conjugated dendrimer (5) and dendron 




and figure S7) at LPS stimulation. Macrophages were also treated with ibuprofen in the presence of 
cationic dendrimer18 and dendron 19. As expected and in line with previous results,63 LPS activates 
M1 macrophages to produce pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-
α)(figure 5A and 6A), IL-1β (figure 5B and 6B), also slightly increases the production of IL-8 (figure 
5C and 6C) and in a higher way affects the IL-6 (figure 5D and 6D) and CCL3 (figure 5E and 6E) 
release.62 On the other hand, LPS activates M2 macrophages to produce anti-inflammatory cytokines 
such as IL-10 (figure S6 and S7), confirming that these cells are prepared to respond to stimuli 
releasing anti-inflammatory cytokines.42, 65 Ibuprofen-treated macrophages do not modify some 
cytokines release, since not all of the evaluated cytokines are related with the ibuprofen pathway 
(figure S6 and S7). Concerning proinflammatory cytokines, dendrons(19 and 17) or dendrimers (18 
and 5) treatment blocks the TNF-α release by M1 cells (figure 5A and 6A), showing an important 
advantage compared with ibuprofen treatment, since it does not affect the TNF-α production. TNF-α 
promotes COX-2 induction and prostaglandin E2 (PGE2) production,
66 which is the enzymatic product 
of COX-2.67 Given that compounds 19, 17 and 18 blocks the expression of COX-2 induced by LPS, 
would be interesting to study whether they have a direct effect on this molecule or whether they are 
acting upstream in the cell signaling pathway. In this regard, COX-2 mRNA could be induced by IL-
1β and IL-8, and interestingly,68-72 dendrons (19 and 17) and dendrimer 18 treatment reduces the IL-
1β production by M1 macrophages, both pretreatment (figure 5B) and post-treatment (figure 6B), 
whilst combination of ibuprofen-conjugated cationic dendrimer 5 with LPS increases the IL-1β 
release compared with LPS activation (figure 5B and 6B). It has been reported that compounds 
affecting TNF-α and COX-2 expression, also affect the IL-6 and IL-8 expression,70, 73 therefore, the 
evaluation of these cytokines is interesting. The data show that 17 and 18 pre-treatment were not 
affecting the IL-8 release compared with LPS treatment (figure 5C and S6C), suggesting an 
ibuprofen-like profile over M1 and M2 cells, while 19 pre-treatment slightly increase the IL-8 release 
by M1 regardless it was combine or not with free ibuprofen (figure 5C). Moreover, dendrons (19, 17) 




viral infection, and also reduce CCL3 release by proinflammatory macrophages (figure 5E and 6E), 
despite they were activated with LPS (previously or subsequently, figure 5 and 6, respectively). 
Ibuprofen-conjugated dendrimer5 was the only one of all tested derivatives that increased TNFα 
(figure S6A and S7A) and CCL3 (figure S6E and S7E) secretion by M2 when combined with LPS, 
indicating that M2-treated cells acquire inflammatory properties. Given these results together with the 
induction of COX-2 expression (figure 4B) and changes in the cytokine profile of the M1 (figure 5 and 
6), dendrimer 5 was discard as anti-inflammatory treatment, despite induce a higher secretion of IL-10 
than LPS (figure S6B and S7B). 
 
Figure 6. Cytokines release by M1 macrophages. Quantification of TNFα (A), IL-1β (B), IL-8 
(C), IL-6 (D) and CCL3 (E) release in M1 cultures supernatants. Shown non-treated cells (NT), 









+)11 (LPS+5)for 24 hours. Also shown macrophages treated with LPS for 30 
minutes and after treated with free ibuprofen and HOC2H4OG3(NMe3
+)8 ((LPS+(19+Ibu)) or 
G2O3(NMe3
+)12 ((LPS+(18+Ibu)) for 24 hours. Individual values from one donor are shown. 
 
Summing up, cationic ibuprofen-conjugated dendron 17 presents the best results as anti-
inflammatory agent. It reduces the LPS-induced COX-2 expression and shows an improved effect 
compared with free ibuprofen used as control, since it decreases the inflammatory cytokines in a 
higher way that ibuprofen do it. Dendron 17 decreases TNFα release (figure 5A, 6A, S6A and S7A), 
cytokine involved in systemic inflammation that activates neuthophils, IL-1β (figure 5B and 6B), IL-6 
(figure 5D and 6D) and CCL3 (figure 5E, 6E, S6E and S7E), that is a cytokine involved in the 
recruitment and activation of leukocytes in the acute inflammatory state. Further and interestingly, 
post-treatment with dendron 17 decreases the expression of CCL2 by M2. CCL2 regulates the 
migration and infiltration of monocytes, memory T lymphocytes, and natural killer (NK) cells at 
inflammatory sites.{Deshmane, 2009 #525} Besides, dendron 17 do not increase the expression of IL-
8 (figure 5C, 6C, S6C and S7C) nor CXCL9 (figure S7C and S7D) by M2, indicating that do not 
induce recruitment of leukocytes to infection sites. These results are very encouraging because they 
define the dendron IbuCO2G3(NMe3
+)8 (17) as a drug for a new anti-inflammatory therapy. 
 
CONCLUSIONS 
Cationic carbosilane dendrimers and dendrons with ibuprofen bound through an ester bond can be 
obtained by esterification or nucleophilic substitution, respectively, and further thiol-ene addition. 
This ester bond can be used to release the antiinflammatory moiety, as has been demonstrated by 
treating these compounds with esterease (PLE). 
The inflammatory response of ibuprofen-conjugated dendritic molecules was evaluated on 
macrophages (M1 and M2) and the results were compared with those obtained for corresponding non-





+)8 (17) reduces inflammatory responses in a better 
way than ibuprofen does. Taking into account the potential biomedical applications of this type of 
compounds, for example as microbicides or gene carriers, and that the triggering of inflammatory 
processes is a handicap for their applications, these results suggest that introduction of ibuprofen to 
cationic carbosilane dendrimers and dendrons would diminish problems associated to their use. 
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Ibuprofen-conjugated and non-ibuprofen cationic carbosilane dendritic molecules show important 
antiinflammatory properties on macrophages.  
 
